摘要普萘洛尔是非选择性β肾上腺素受体阻滞剂，多项研究已证实其治疗婴儿血管瘤安全有效，作用机制主要包括：①由周细胞介导的血流动力学改变及后续效应；②阻滞血管瘤来源的内皮细胞和干细胞的细胞周期进程从而抑制其增殖，诱导血管瘤来源的内皮细胞凋亡和血管瘤来源的干细胞向脂肪细胞分化；③抑制内皮祖细胞的募集；④降低促血管生成因子（如血管内皮生长因子、基质金属蛋白酶等）的水平。

abstractsPropranolol is a non-selective β-adrenoceptor blocker. Various studies have confirmed that it is safe and effective for the treatment of infantile hemangioma. The mechanism of action mainly includes: (1) pericyte-mediated hemodynamic changes and subsequent effects; (2) inhibiting proliferation of hemangioma-derived endothelial cells and stem cells by blocking cell cycle progression, inducing apoptosis of hemangioma-derived endothelial cells and differentiation of hemangioma-derived stem cells into adipocytes; (3) inhibiting the recruitment of endothelial progenitor cells; (4) reducing levels of pro-angiogenic factors, such as vascular endothelial growth factor, matrix metalloproteinase, etc.